Inclusion Criteria:

- Diagnosis of recurrent/progressive WHO grade IV MG or WHO grade III MG. Pts with
prior low-grade glioma are eligible if histologic assessment demonstrates
transformation to WHO grade III / IV MG

- >18 yrs

- Karnofsky Performance Status >70 percent

- Pts presenting in 1st, 2nd / 3rd relapse. Prior therapy must have included external
beam XRT

- Adequate bone marrow, liver & renal function as assessed by following:

- Hemoglobin>9.0g/dl

- ANC>1,500/mm3

- Platelet count>100,000/mm3

- Total bilirubin<1.5 x ULN

- ALT & AST<2.5 x ULN

- INR<1.5 or PT/PTT within normal limits. Pts receiving anti-coagulation treatment w
low-molecular weight heparin allowed to participate, oral warfarin is not permitted

- Creatinine<1.5 x ULN

- Serum Na, K+, Mg2+, Phosphate & Ca2+ >LLN

- Interval<2 wks between prior surgical resection & initiation of study regimen

- Interval <12 weeks from completion of standard, daily XRT, unless one of following
occurs: new area of enhancement on MRI imaging that is outside XRT field; biopsy
proven recurrent tumor; / radiographic evidence of progressive tumor on 2 consecutive
scans >4 wks apart.

- Interval <4weeks from prior chemotherapy unless there is unequivocal evidence of
tumor progression & pt has recovered from all anticipated toxicities from prior
therapy

- Interval <4weeks from prior investigational agent unless there is unequivocal
evidence of tumor progression & pt has recovered from all anticipated toxicities from
prior therapy

- Signed written informed consent including HIPAA according to institutional
guidelines. Signed informed consent must be obtained prior to any study specific
procedures

- If sexually active, pts will take contraceptive measures for duration of treatments &
for 4 weeks following discontinuation of dasatinib & Erlotinib.

- Women of childbearing potential must have negative serum or urine pregnancy test
within 72 hrs prior to start of study drug administration

Exclusion Criteria:

- No prior dasatinib / oral EGFR-inhibitor therapy

- Pregnancy/breast feeding

- History of significant concurrent illness

->3 prior episodes of progressive disease

- Significant cardiac disease

- Excessive risk of bleeding as defined by stroke <6 months, history of CNS /
intraocular bleed,/ septic endocarditis.

- Concurrent severe and/or uncontrolled medical disease that could compromise
participation in study including any of following: pleural / pericardial effusion of
any grade; uncontrolled diabetes; uncontrolled hypertension; active clinically
serious infection >CTCAEv3 Gr2 requiring active intervention; history of
clinically-significant bleeding diathesis or coagulopathy including platelet function
disorder or acquired bleeding disorder within 1yr; impairment of GI function /GI
disease that may significantly alter absorption of study regimen; ongoing or recent
significant gastrointestinal bleeding

- Thrombolic or embolic events such as cerebrovascular accident including transient
ischemic attacks <6 months

- Any hemorrhage/bleeding event >CTCAEv3AE Gr3 within 4wks of 1st dose of study drug

- Serious non-healing wound, ulcer, /bone fracture

- Major surgery, open biopsy /significant traumatic injury <4 weeks of 1st study drug

- Known HIV infection/chronic Hepatitis B/C

- Pt is <3yrs free of another primary malignancy except: if other primary malignancy is
either not currently clinically significant/does not require active intervention.
Existence of any other malignant disease is not allowed.

- Pts unwilling to/unable to comply with protocol including ability to swallow whole
pills/presence of any malabsorption syndrome

- Concurrent administration of warfarin, rifampin/St. John's Wort

- Subjects w hypokalemia/hypomagnesemia if it cannot be corrected

- Prisoners/subjects who are compulsorily detained for treatment of either
psychiatric/physical illness